RS59066B1 - Jedinjenja amida kao agonisti 5-ht4 receptora - Google Patents
Jedinjenja amida kao agonisti 5-ht4 receptoraInfo
- Publication number
- RS59066B1 RS59066B1 RS20190836A RSP20190836A RS59066B1 RS 59066 B1 RS59066 B1 RS 59066B1 RS 20190836 A RS20190836 A RS 20190836A RS P20190836 A RSP20190836 A RS P20190836A RS 59066 B1 RS59066 B1 RS 59066B1
- Authority
- RS
- Serbia
- Prior art keywords
- receptor agonists
- amide compounds
- amide
- compounds
- agonists
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- -1 Amide compounds Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN709CH2015 | 2015-02-13 | ||
PCT/IN2016/000008 WO2016128990A1 (en) | 2015-02-13 | 2016-01-07 | Amide compounds as 5-ht4 receptor agonists |
EP16711355.4A EP3265459B1 (en) | 2015-02-13 | 2016-01-07 | Amide compounds as 5-ht4 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
RS59066B1 true RS59066B1 (sr) | 2019-09-30 |
Family
ID=55588327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20190836A RS59066B1 (sr) | 2015-02-13 | 2016-01-07 | Jedinjenja amida kao agonisti 5-ht4 receptora |
Country Status (30)
Country | Link |
---|---|
US (1) | US9957257B2 (sr) |
EP (1) | EP3265459B1 (sr) |
JP (1) | JP6487564B2 (sr) |
KR (1) | KR101966576B1 (sr) |
CN (1) | CN107406434B (sr) |
AU (1) | AU2016217461B2 (sr) |
BR (1) | BR112017017275A2 (sr) |
CA (1) | CA2975973C (sr) |
CY (1) | CY1121898T1 (sr) |
DK (1) | DK3265459T3 (sr) |
EA (1) | EA034618B1 (sr) |
ES (1) | ES2734734T3 (sr) |
HR (1) | HRP20191179T1 (sr) |
HU (1) | HUE045667T2 (sr) |
IL (1) | IL253848B (sr) |
LT (1) | LT3265459T (sr) |
MA (1) | MA41633B1 (sr) |
MD (1) | MD3265459T2 (sr) |
ME (1) | ME03430B (sr) |
MX (1) | MX368214B (sr) |
NZ (1) | NZ734400A (sr) |
PL (1) | PL3265459T3 (sr) |
PT (1) | PT3265459T (sr) |
RS (1) | RS59066B1 (sr) |
SG (1) | SG11201706501VA (sr) |
SI (1) | SI3265459T1 (sr) |
SM (1) | SMT201900398T1 (sr) |
TR (1) | TR201909997T4 (sr) |
WO (1) | WO2016128990A1 (sr) |
ZA (1) | ZA201705292B (sr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2619829T3 (es) | 2011-11-18 | 2017-06-27 | Heptares Therapeutics Limited | Agonistas del receptor muscarínico M1 |
GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201709652D0 (en) | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
CN110818661B (zh) * | 2019-12-02 | 2021-08-06 | 上海再启生物技术有限公司 | 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005049608A1 (en) | 2003-11-24 | 2005-06-02 | Pfizer Japan, Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
CA2598516C (en) | 2005-02-25 | 2010-05-11 | Pfizer Inc. | Benzisoxazole derivatives |
US7906532B2 (en) | 2005-07-22 | 2011-03-15 | Pfizer Inc. | Indazole derivatives |
WO2007048643A1 (en) * | 2005-10-28 | 2007-05-03 | Glaxo Group Limited | Novel compound |
GB0525661D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
GB0603550D0 (en) | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
RU2569733C2 (ru) * | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
MX2012008721A (es) | 2010-02-16 | 2012-08-17 | Pfizer | (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4. |
RS53940B1 (sr) * | 2011-09-19 | 2015-08-31 | Suven Life Sciences Limited | Heteroaril jedinjenja kao ligandi 5-ht4 receptora |
AU2013382944B2 (en) * | 2013-03-20 | 2016-08-04 | Suven Life Sciences Limited | 5-Amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists |
WO2015092804A1 (en) * | 2013-12-16 | 2015-06-25 | Suven Life Sciences Limited | Indazole compounds as 5-ht4 receptor agonists |
-
2016
- 2016-01-07 CN CN201680015614.4A patent/CN107406434B/zh not_active Expired - Fee Related
- 2016-01-07 MX MX2017010348A patent/MX368214B/es active IP Right Grant
- 2016-01-07 MA MA41633A patent/MA41633B1/fr unknown
- 2016-01-07 KR KR1020177025584A patent/KR101966576B1/ko not_active Expired - Fee Related
- 2016-01-07 NZ NZ734400A patent/NZ734400A/en not_active IP Right Cessation
- 2016-01-07 PT PT16711355T patent/PT3265459T/pt unknown
- 2016-01-07 ME MEP-2019-190A patent/ME03430B/me unknown
- 2016-01-07 EP EP16711355.4A patent/EP3265459B1/en active Active
- 2016-01-07 JP JP2017542107A patent/JP6487564B2/ja not_active Expired - Fee Related
- 2016-01-07 TR TR2019/09997T patent/TR201909997T4/tr unknown
- 2016-01-07 CA CA2975973A patent/CA2975973C/en not_active Expired - Fee Related
- 2016-01-07 HU HUE16711355A patent/HUE045667T2/hu unknown
- 2016-01-07 HR HRP20191179TT patent/HRP20191179T1/hr unknown
- 2016-01-07 WO PCT/IN2016/000008 patent/WO2016128990A1/en active Application Filing
- 2016-01-07 SM SM20190398T patent/SMT201900398T1/it unknown
- 2016-01-07 LT LTEP16711355.4T patent/LT3265459T/lt unknown
- 2016-01-07 SI SI201630311T patent/SI3265459T1/sl unknown
- 2016-01-07 MD MDE20180052T patent/MD3265459T2/ro not_active IP Right Cessation
- 2016-01-07 SG SG11201706501VA patent/SG11201706501VA/en unknown
- 2016-01-07 AU AU2016217461A patent/AU2016217461B2/en not_active Ceased
- 2016-01-07 DK DK16711355.4T patent/DK3265459T3/da active
- 2016-01-07 US US15/549,663 patent/US9957257B2/en active Active
- 2016-01-07 EA EA201791829A patent/EA034618B1/ru unknown
- 2016-01-07 RS RS20190836A patent/RS59066B1/sr unknown
- 2016-01-07 ES ES16711355T patent/ES2734734T3/es active Active
- 2016-01-07 PL PL16711355T patent/PL3265459T3/pl unknown
- 2016-01-07 BR BR112017017275A patent/BR112017017275A2/pt not_active IP Right Cessation
-
2017
- 2017-08-04 ZA ZA2017/05292A patent/ZA201705292B/en unknown
- 2017-08-06 IL IL253848A patent/IL253848B/en active IP Right Grant
-
2019
- 2019-07-10 CY CY20191100739T patent/CY1121898T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253848A0 (en) | Amine compounds as 5-hydroxytryptamine 4 receptor agonists | |
IL248347A0 (en) | Compounds and preparations as agonists of toll-like receptor 7 | |
IL248311A0 (en) | Compounds and preparations as agonists of toll-like receptor 7 | |
GB201514875D0 (en) | Receptor | |
GB201518816D0 (en) | Receptor | |
SI3609898T1 (sl) | Spojine, uporabne kot zaviralci RET | |
ZA201604527B (en) | Compounds for use as gpr120 agonists | |
IL256226A (en) | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors | |
ZA201701755B (en) | Fused heterocyclic compounds as gpr120 agonists | |
IL247143B (en) | A new use of agonistic compounds for the sigma-1 receptor | |
IL245948B (en) | 5–ht4 indazole compounds as receptor agonists | |
GB201619637D0 (en) | C3a receptor agonists | |
DK3142666T3 (da) | 5-HT4-receptoragonist til gastroparese | |
PL3247719T3 (pl) | Białka agonistów receptora MET | |
GB201500297D0 (en) | Agonists | |
AU361570S (en) | Trough | |
GB201419430D0 (en) | Dopamine D3 receptor antagonist compounds | |
GB201419433D0 (en) | Dopamine D3 receptor antagonist compounds |